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Introduction
An increasing incidence of pancreatic cancer has made the
disease the fifth leading cause of cancer death in the USA
[1] and the sixth in the UK [2]. The overall prognosis is
extremely poor, only 10% of patients being alive 1 year
after diagnosis and <3% at 5 years [2–4]. Excluding
ampullary carcinomas, only a minority of pancreatic can-
cers are suitable for operation, which offers the only hope
of long-term survival. 
With the recent description of intraductal papillary
mucinous tumour (IPMT), a subgroup of pancreatic
tumours – premalignant and malignant – has been identi-
fied for which aggressive surgical treatment is worthwhile
and can be strongly recommended [5–15]. A few hundred
cases of IPMT have been described, but follow-up is sparse
and short. Total pancreatectomy has been reported with
follow-up in only 12 patients from seven centres [16–22].
We therefore believe that it is important to present our
experience of seven patients with IPMT, six of whom were
operable and underwent a total pancreatectomy.
Patients and methods
During the last 5 years seven men with IPMT were diag-
nosed in this department. The median age was 68 years
(range 39–75 years). All patients had a preoperative ultra-
sound scan (US) and endoscopic retrograde
cholangiopancreatography (ERCP) with brush cytology.
Three had a computed tomography (CT) scan and one a
magnetic resonance (MR) scan. Fine-needle aspiration
cytology (FNAC) was performed preoperatively in six
patients. Preoperative biopsies were taken when needed.
One 75-year-old man with biopsy-verified metastases in the
liver was not operated. The other six patients recieved a
total pancreatectomy. The clinical and demographic data
are shown in Table 1. Patients were followed-up in their
own county by specialists in internal medicine or
endocrinology.
Histology
The pancreatectomy specimens (Figure 1) were meticu-
lously investigated by the pathologist. The histology of the
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tumours was described according to the WHO classifica-
tion [23,24] as follows. (1) Intraductal papillary mucinous
adenomas were papillary mucin-producing tumours with
little or no cellular atypia. (2) Borderline papillary muci-
nous tumours were moderately dysplastic (hyperchromatic
polarised nuclei with an occasional distinct nucleolus,
nuclear crowding and stratification, variable mucin con-
tent). With adenomas the papillary projections had a
fibrovascular stalk. (3) Intraductal papillary mucinous car-
cinoma, non-invasive, showed in-situ carcinoma of the
papillary proliferations (nuclear pleomorphism, prominent
nucleoli, mitotic figures of the epithelial cells with papillae
without a fibrovascular stalk, cribriform pattern). (4)
Intraductal papillary mucinous carcinoma, invasive. As for
(3), but with clear signs of stromal invasion (Figure 2). 
Results
The results of the US, FNAC, CT, MR, ERCP and brush
cytology are shown in Table 1. All seven patients had
diffuse dilatation of the main pancreatic duct. Six patients
underwent total pancreatectomy, while the seventh lived
for 17 months without operation despite the presence of
histologically proven liver metastases. Patient no. 3 was
operated on suspicion of mucinous cystadenoma or cysta-
denocarcinoma in the pancreatic head. A Whipple’s
procedure was performed, and frozen section of the resec-
tion margin of the pancreas showed no tumour. This
judgement was wrong: after further examination mucin-
producing adenoma was detected at the resection margin.
Ten days later the patient was reoperated for leakage from
the pancreaticojejunostomy, and the rest of the pancreas
was then removed.
The widespread extension of papillary tumour in all six
operated patients is illustrated in Figure 3. The morphology
of these six tumours is shown in Table 2. All six operated
patients are alive 5–56 months after total pancreatectomy,
having regained their preoperative weight.
Only one patient needed daily strong analgesics. He
had a 15-year history of Crohn’s disease and was addicted to
strong medication before the operation. Steatorrhoea was
effectively treated in each patient by means of a low-fat diet
and pancreatic enzyme substitution (6–12 Pancreon daily:
median 9), and no patient had more than two stools per
day. 
Diabetes mellitus was moderately well regulated in all
patients with Hgb A1c fractions between 0.062 and 0.099
(median 0.084; normal range: 0.044–0.064). None experi-
enced diabetic ketoacidosis. 
Discussion
In 1982 Ohhashi et al. [25] described the clinical criteria
associated with a specific group of neoplasms in the pan-
creas. The four criteria were as follows: an ectatic main
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Figure 1. Pancreatectomy specimen from case no. 4, in which an intraductal
papillary mucinous carcinoma was confined to the main duct and side branches
of the head and neck of the pancreas.The main duct is distended and there is
severe chronic obstructive pancreatitis of the whole organ.
Figure 2. Part of dilated main duct in case no. 2 with severely dysplastic
papillary epithelium representing an intraductal papillary mucinous carcinoma.
Haematoxylin and eosin (340).
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Table 2. Morphology of the six intraductal papillary pancreatic tumours 
Patient Type Extent and secondary changes
1 IPMC (I) Severe dysplastic changes practically confined to the body and tail with early invasion of the body
Main duct and side branches. Slight obstructive pancreatitis of the head and moderate/severe of the
body and tail
2 IPMC (N) Widespread severe dysplasia in main duct and side branches throughout the pancreas
Severe obstructive pancreatitis of the whole organ
3 IPMA Slight dysplasia in the main duct and side branches of the head and in few scattered foci of the
body and tail
Severe obstructive pancreatitis of the head, slight in body and tail
4 IPMC (susp.I) Severe dysplasia with focus of suspected invasion 
Changes confined to the main duct and side branches of head and neck
Severe obstructive pancreatitis of the whole organ
5 IPMC (N) Widespread moderate-to-severe dysplasia in main duct and side branches of the entire pancreas
Moderate obstructive pancreatitis of the head – severe in body and tail
6 IPMC (N) Focal dysplasia in side branches of the head and large focus in main duct of the body with
moderate and severe dysplasia
Moderate obstructive pancreatitis of the head – severe in body and tail
IPMA = intraductal papillary mucinous adenoma; IPMC = intraductal papillary mucinous carcinoma; N = noninvasive; I = invasive;
susp.I = suspicious for invasion.
Table 1. Demographic data on seven male IPMT patients diagnosed between 1994 and 1998
Case Age (yr) Symptoms US FNAC CT MR ERCP/brush cytology
1 46 pain, cyst cyst, – communicating cysts/dysplasia, mucin,
loss of weight – duct ectasia duct ectasia
2 68 loss of weight, multi-cystic – – IPMT/CIS, duct ectasia
steatorrhoea
3 54 loss of weight, cystic mass – – duct ectasia, normal cells, mucin,
steatorrhoea in caput, communicating cysts
normal cells
4 73 loss of weight, mass in head mass in head – duct ectasia, severe dysplasia, mucin
pain, of pancreas, of pancreas
steatorrhoea normal cells
5 65 pain, diabetes, mass in caput, dilated duct duct ectasia duct ectasia, dysplasia, mucin, tumour
loss of weight, dilated duct, with tumour 
alcohol normal cells in duct
6 39 pain, dilated duct – – duct ectasia, normal cells, suspicion for  
loss of weight, either tumour or mucin (filling defect).
pancreatitis
7 75 loss of weight liver metastases – – duct ectasia, dysplasia, mucin
carcinoma
US = ultrasound; FNAC = fine-needle aspiration cytology; CT = computed tomography; MR = magnetic resonance imaging; ERCP = endoscopic retrograde
cholangiopancreatography; IPMT = intraductal papillary mucinous tumour; CIS = carcinoma in situ; caput = head of pancreas.
pancreatic duct, mucin secretion, secretion of mucin
through a patulous papilla and the presence of a mucin-
producing papillary intraductal tumour (IPMT). IPMTs
account for 0.5% of pancreatic tumours found at autopsy,
7.5% of clinically diagnosed tumours and 16.3% of tumours
in resected cases [23]. IPMTs were subclassified in 1992 by
Furokawa et al. [26] into four types according to their gross
features: type 1, diffusely dilated main duct; type 2, focally
dilated main duct; type 3, cystic sub-branches; type 4,
dilated sub-branches. Type 1 seems to be the most common
and all the present cases belong to this group.
Weight loss was seen in all our patients. This feature
together with other symptoms of chronic pancreatitis,
such as pain, steatorrhoea, and diabetes [27], should lead
to a suspicion of IPMT [17,28]. Recurrent or chronic
pancreatitis without a known aetiological cause might
lead the surgeon to suspect an intraductal obstruction [5],
and the appropriate investigations should then be
performed.
All seven patients in the present study were men, and
the lesions involved the pancreatic head in every case.
These characteristics separate IPMT from mucinous cystic
neoplasms (MCN) [29], with which they otherwise have
much in common. Both tumours originate from the duct
epithelium and carry a relatively favourable prognosis,
while MCN mainly affect middle-aged women, are mainly
located in the body and tail of the pancreas, and do not
usually communicate with the duct system. 
US and CT will often suggest the diagnosis of IPMT
[30,31], but in our experience they are very imprecise. All
our patients were diagnosed by ERCP. The endoscopic find-
ings of mucin leaking from the papilla, dilated pancreatic
duct and filling defects due to mucin or papillomatous
tumour all point to IPMT [32–34]. ERCP with brush
cytology and/or biopsy is the gold standard for evaluating
patients suspected of IPMT. 
The six operated patients received a total pancreat-
ectomy due to the diffuse nature of the disease. Multifocal
changes were subsequently found in the duct system in all
but one patient (Figure 3). Indeed the reconstruction study
of Furokawa and co-workers [26] showed that in the diffuse
type of IPMT the tumour involved a wide ductal area,
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Figure 3. Schematic drawings of localis-
ation of the papillary tumours in six
patients. Open circles over the main duct
represent in-situ main duct localisation.
Open circles outside the main duct repre-
sent changes in side branches. In one
patient (case no. 1) the closed circle in the
body of the pancreas represents a focus of
early invasion.
while Loftus and colleagues [19] demonstrated dysplastic
epithelial changes throughout the entire duct system in the
same subtype, which led them to advocate total pancrea-
tectomy. In the other three types of IPMT, in which there
are localised changes, a limited resection could be consid-
ered, although ductal changes can still extend into
apparently normal segments either continuously or discon-
tinuously [26]. Thus at least a free resection margin is
required plus careful follow-up. 
In reviewing the treatment of 194 patients with IPMT
in 17 centres worldwide, we found that about half of them
were treated with Whipple’s procedure and only 10%
(including our own six patients) had a total pancreat-
ectomy. There is no doubt that IPMT is a precancerous
condition; at least 10% of cases are invasive at operation.
The problem is that the course of this comparatively rare
disease is uncertain. The risk of leaving IPMT in remaining
pancreatic tissue is not well described, but Barbe et al. [28]
reviewed three patients retrospectively and six inoperable
patients prospectively with serial ERCPs over a period of
6–50 months. Some progression of duct dilatation and
mucin amount were observed in four patients, but no
patient died of the disease during this time. Brat et al. [35]
presented two cases (one Whipple procedure and one distal
resection) in which papillary hyperplasia in one and atypi-
cal hyperplasia at the resection margin in the other was
followed by adenocarcinoma in the remnant pancreas after
9 and 10 years respectively. 
It is important to note that these patients are not
asymptomatic; most of them suffer variably from symptoms
of chronic pancreatitis. Concerns about the radical nature
of total pancreatectomy are based on the presumed difficul-
ties in treating the resulting exocrine and endocrine
insufficiency, but in the present series control was satisfac-
torily achieved. 
In conclusion, IPMT represents a subgroup of pancreatic
neoplasms with a very slow progression to manifest cancer.
The diagnosis may be suspected in patients with non-
alchoholic chronic pancreatitis. US, CT and MR imaging
may lead to suspicion of IPMT, and ERCP with brush
cytology very often provides the diagnosis. Histological
heterogeneity makes exclusion of a malignant focus very dif-
ficult. The prognosis is very favourable. At operation the
entire dysplastic epithelium should be removed. In our
experience in which the final pathology demonstrated wide-
spread and discontinuous lesions, total pancreatectomy was
required and was tolerated in all six patients.
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